https://www.selleckchem.com/pr....oducts/Carboplatin.h
02), AFP ≥100 (60% versus 77%, p=0.049), and multiple viable tumors on last imaging before LT (70% versus 83%, p=0.002). CONCLUSION In this analysis of HCC patients receiving DCD versus DBD livers in the UNOS database, we found that patients with a low to moderate risk of HCC recurrence (80-90% of the DCD cohort) had equivalent survival regardless of donor type. It appears that DCD donation can best be utilized to increase the donor pool for HCC patients with decompensated cirrhosis or partial response/stable disease after local-reg
Like
Comment
Share
